RxDoctor Payments Data

Melissa Summerfield

Ophthalmology · Mason City, IANPI 1609096478

Payments from drug & device makers

$1,562in general payments, 2019–2025

Across 44 payments — averaging $35.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$365
  • Rxsight Inc$249
  • Mallinckrodt Hospital Products Inc.$182
  • AbbVie$177
  • Amgen$124
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$66
  • plus $399 from 13 others

What the payments were for

  • Travel & lodging$121%
  • Food & beverage$1,55099%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,562 in reported general payments places this provider in the 55th percentile of 172 ophthalmology providers in Iowa.

See all ophthalmology providers in Iowa

Medicare billing

Part B allowed, 2024
$674,636
Medicare patients
1,518
Services billed
6,967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine49$45,027
LumiganBimatoprost79$30,150
ProlensaBromfenac Sodium46$16,341
Prednisolone Acetate212$10,490
RocklatanNetarsudil Mesylat/Latanoprost29$9,869
Latanoprost972$8,318
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat408$7,336
Travoprost20$4,802
Brimonidine Tartrate177$4,685
RhopressaNetarsudil Mesylate13$4,061
MoxifloxacinMoxifloxacin Hcl104$3,137
Timolol Maleate185$1,965
Dorzolamide Hcl89$1,179
ErythromycinErythromycin Base86$1,022
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$177$75,177128 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$66$16,34146 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$17$13,93042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 172 ophthalmology providers in Iowa.

Other ophthalmology in Mason City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →